To explore the therapeutic potential of targeting PTP1B and PTPN2 in cancer with a small molecule inhibitor, we took advantage of AbbVie’s/Calico’s Compound 182, which inhibits both PTP1B and PTPN2 and is related to the small molecule drug ABBV-CLS-484 (Supplementary Figs. 1 and 2) currently in clinical trials. The gene discussed is PTPN1; the disease is cancer.